Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation

Virology

Volumn 260, Issue 1, 1999, Pages 125-135

  Skiadopoulos, Mario H ^a   Surman, Sonja R ^a   St Claire, Marisa ^b   Elkins, William R ^a   Collins, Peter L ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BIOQUAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; GENE MUTATION; IMMUNIZATION; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS GENE;

EID: 0033587598     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9802     Document Type: Article

References (42)

1. Belshe R. B., Hissom F. K. Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markers. J. Med. Virol. 10:1982;235-242.
2. Bukreyev A., Whitehead S. S., Murphy B. R., Collins P. L. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:1997;8973-8982.
3. Collins P. L., Chanock R. M., McIntosh K. Parainfluenza Viruses. Fields B. N., Knipe D. M., Howley P. M., Chanock R. M., Melnick J. L., Monath T. P., Roizman B., Straus S. E. Fields Virology. 1996;1205-1243 Lippincott-Raven Publishers, Philadelphia.
4. Collins P. L., Hill M. G., Camargo E., Grosfeld H., Chanock R. M., Murphy B. R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA. 92:1995;11563-11567.
5. Crookshanks F. K., Belshe R. B. Evaluation of coldadapted and temperature-sensitive mutants of parainfluenza virus type 3 in weanling hamsters. J. Med. Virol. 13:1984;243-249.
6. Crowe J. E. Jr., Bui P. T., Davis A. R., Chanock R. M., Murphy B. R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 12:1994a;783-790.
7. Crowe J. E. Jr., Bui P. T., London W. T., Davis A. R., Hung P. P., Chanock R. M., Murphy B. R. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine. 12:1994b;691-699.
8. Crowe J. E. Jr., Bui P. T., Siber G. R., Elkins W. R., Chanock R. M., Murphy B. R. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine. 13:1995;847-855.
9. Crowe J. E. Jr., Cheung P. Y., Wallace E. F., Chanock R. M., Larrick J. W., Murphy B. R., Fry K. Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus. Clin. Diagn. Lab. Immunol. 1:1994c;701-706.
10. Crowe, J. E. Jr., Collins, P. L., Chanock, R. M., and Murphy, B. R.1997. Vaccines against respiratory syncytial virus and parainfluenza virus type 3. InNew Generation Vaccines (M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon, Eds.), 2nd. Ed.), pp. 711-725. Marcel Dekker, New York.
11. Durbin A. P., Cho C. J., Elkins W. R., Wyatt L. S., Moss B., Murphy B. R. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with that of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J. Infect. Dis. 179:1999;1345-1351.
12. Durbin A. P., Hall S. L., Siew J. W., Whitehead S. S., Collins P. L., Murphy B. R. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology. 235:1997;323-332.
13. Garcin D., Itoh M., Kolakofsky D. A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture. Virology. 238:1997;424-431.
14. Hall S. L., Sarris C. M., Tierney E. L., London W. T., Murphy B. R. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees. J. Infect. Dis. 167:1993;958-962.
15. Hall S. L., Stokes A., Tierney E. L., London W. T., Belshe R. B., Newman F. C., Murphy B. R. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:1992;173-184.
16. Hoffman M. A., Banerjee A. K. An infectious clone of human parainfluenza virus type 3. J. Virol. 71:1997;4272-4277.
17. Horikami S. M., Moyer S. A. Alternative amino acids at a single site in the Sendai virus L protein produce multiple defects in RNA synthesis in vitro. Virology. 211:1995;577-582.
18. Juhasz K., Whitehead S. S., Boulanger C. A., Firestone C. Y., Collins P. L., Murphy B. R. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine. 17:1999;1416-1424.
19. Juhasz K., Whitehead S. S., Bui P. T., Biggs J. M., Boulanger C. A., Collins P. L., Murphy B. R. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:1997;5814-5819.
20. Karron R. A., Wright P. F., Crowe J. E. Jr., Clements M. L., Thompson J., Makhene M., Casey R., Murphy B. R. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J. Infect. Dis. 176:1997;1428-1436.
21. Karron R. A., Wright P. F., Hall S. L., Makhene M., Thompson J., Burns B. A., Tollefson S., Steinhoff M. C., Wilson M. H., Harris D. O., Clements M. L., Murphy B. R. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J. Infect. Dis. 171:1995a;1107-1114.
22. Karron R. A., Wright P. F., Newman F. K., Makhene M., Thompson J., Samorodin R., Wilson M. H., Anderson E. L., Clements M. L., Murphy B. R., Belshe R. B. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172:1995b;1445-1450.
23. Kato A., Kiyotani K., Sakai Y., Yoshida T., Nagai Y. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J. 16:1997a;578-587.
24. Kato A., Kiyotani K., Sakai Y., Yoshida T., Shioda T., Nagai Y. Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. J. Virol. 71:1997b;7266-7272.
25. Kondo T., Yoshida T., Miura N., Nakanishi M. Temperature-sensitive phenotype of a mutant Sendai virus strain is caused by its insufficient accumulation of the M protein. J. Biol. Chem. 268:1993;21924-21930.
26. Kurotani A., Kiyotani K., Kato A., Shioda T., Sakai Y., Mizumoto K., Yoshida T., Nagai Y. Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes Cells. 3:1998;111-124.
27. Mbiguino A., Menezes J. Purification of human respiratory syncytial virus: superiority of sucrose gradient over percoll, renografin, and metrizamide gradients. J. Virol. Methods. 31:1991;161-170.
28. Murphy B. R., Sotnikov A. V., Lawrence L. A., Banks S. M., Prince G. A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 8:1990;497-502.
29. Poch O., Blumberg B. M., Bougueleret L., Tordo N. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J. Gen. Virol. 71:1990;1153-1162.
30. Prince G. A., Suffin S. C., Prevar D. A., Camargo E., Sly D. L., London W. T., Chanock R. M. Respiratory syncytial virus infection in owl monkeys: Viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants. Infect. Immunol. 26:1979;1009-1013.
31. Roberts A., Rose J. K. Recovery of negative-strand RNA viruses from plasmid DNAs: A positive approach revitalizes a negative field. Virology. 247:1998;1-6.
32. Skiadopoulos M. H., Durbin A. P., Tatem J. M., Wu S. L., Paschalis M., Tao T., Collins P. L., Murphy B. R. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72:1998;1762-1768.
33. Skiadopoulos M. H., Surman S., Tatem J. M., Paschalis M., Wu S.-L., Udem S. A., Durbin A. P., Collins P. L., Murphy B. R. Identification of mutations contributing to the temperature sensitive, cold-adapted, and attenuation phenotypes of the live attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol. 73:1999;1374-1381.
34. Stec D. S., Hill M. G., Collins P. L. Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology. 183:1991;273-287.
35. Subbarao E. K., Park E. J., Lawson C. M., Chen A. Y., Murphy B. R. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. J. Virol. 69:1995;5969-5977.
36. Tao T., Durbin A. P., Whitehead S. S., Davoodi F., Collins P. L., Murphy B. R. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J. Virol. 72:1998;2955-2961.
37. van Wyke Coelingh K. L., Winter C., Murphy B. R. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology. 143:1985;569-582.
38. Whitehead S. S., Bukreyev A., Teng M. N., Firestone C. Y., St. Clair M., Elkins W. R., Collins P. L., Murphy B. R. Recombinant respiratory syncytial virus (RSV) bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73:1999;3438-3442.
39. Whitehead S. S., Firestone C. Y., Collins P. L., Murphy B. R. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology. 247:1998a;232-239.
40. Whitehead S. S., Firestone C. Y., Karron R. A., Crowe J. E. J., Elkins W. R., Collins P. L., Murphy B. R. Addition of a missense mutation present in the L gene of respiratory syncytial Virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol. 73:1999b;871-877.
41. Whitehead S. S., Juhasz K., Firestone C. Y., Collins P. L., Murphy B. R. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J. Virol. 72:1998b;4467-4471.
42. Wyatt L. S., Moss B., Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology. 210:1995;202-205.